Melanie Gloria Biography and Net Worth

COO of Immunovant

After a successful nursing career, Melanie joined the pharmaceutical industry to fulfill her personal mission to have a broader impact on patients’ lives. Melanie has over 20 years of experience in operational roles in the biotechnology industry. Her experience spans across all phases of development and multiple therapeutic areas. Prior to joining Immunovant, Melanie was the Chief Operating Officer at ACELYRIN where she was responsible for all operational functions and the company’s operating governance. Prior to ACELYRIN Melanie worked at Horizon Therapeutics and led the build out of R&D capabilities. Melanie’s foundational pharmaceutical industry experience started with her time at Abbott and AbbVie. Melanie received her BS in Nursing from University of Illinois, Chicago.

What is Melanie Gloria's net worth?: The estimated net worth of Melanie Gloria is at least $6.23 million as of October 7th, 2026. Gloria owns 217,060 shares of Immunovant stock worth more than $6,231,793 as of October 14th. This net worth estimate does not reflect any other assets that Gloria may own. Learn More about Melanie Gloria's net worth.
How do I contact Melanie Gloria?: The corporate mailing address for Gloria and other Immunovant executives is 1000 Park Forty Plaza, Durham, NC, 27713. Immunovant can also be reached via phone at (917) 410-3120 and via email at [email protected]. Learn More on Melanie Gloria's contact information.
Has Melanie Gloria been buying or selling shares of Immunovant?: Within the last three months, Melanie Gloria has sold $71,846.46 in shares of Immunovant stock. Most recently, Melanie Gloria sold 2,241 shares of the business's stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $32.06, for a transaction totalling $71,846.46. Following the completion of the sale, the chief operating officer now directly owns 217,060 shares of the company's stock, valued at $6,958,943.60. Learn More on Melanie Gloria's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Andrew Fromkin (Director), Michael Geffner (Chief Medical Officer), Tiago Girão (CFO), Melanie Gloria (COO), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), Frank Torti (Director), Christopher Van Tuyl (Chief Legal Officer and Corporate Secretary), and Eric Venker (CEO). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,666,666 shares worth more than $349,999,986.00. During the last twelve months, insiders at the sold shares 33 times. They sold a total of 481,163 shares worth more than $15,434,169.67. The most recent insider tranaction occured on October, 7th when CTO Jay S. Stout sold 3,809 shares worth more than $122,116.54. Insiders at Immunovant own 1.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 10/7/2026.

Melanie Gloria Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/7/2026	Sell	2,241	$32.06	$71,846.46	217,060
7/8/2026	Sell	2,036	$39.55	$80,523.80	222,357
6/26/2026	Sell	17,714	$38.31	$678,623.34	224,393
4/8/2026	Sell	8,722	$24.83	$216,567.26	245,222
11/20/2025	Sell	12,626	$23.62	$298,226.12	173,511

Melanie Gloria Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $28.71

$28.70

$29.64

50 Day Range

MA: $38.02

$28.71

$44.96

2 Week Range

Now: $28.71

$16.77

$45.42

Volume

1,242,634 shs

Average Volume

1,692,891 shs

Market Capitalization

$5.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84